In vitro activity of cefiderocol in combination with new β-lactam/β-lactamase inhibitor combinations (βL-βLICs) against multidrug resistant KPC-producing Klebsiella pneumoniae-Reference-Cited by-同舟云学术

In vitro activity of cefiderocol in combination with new β-lactam/β-lactamase inhibitor combinations (βL-βLICs) against multidrug resistant KPC-producing Klebsiella pneumoniae

Published:2023-08-30 Issue:11 Volume:76 Page:682-688
ISSN:0021-8820
Container-title:The Journal of Antibiotics
language:en
Short-container-title:J Antibiot

Author:

Gaibani Paolo,Lazzarotto Tiziana,Viale PierLuigi,Ambretti Simone

Funder

Ministero della Salute

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology

Link

https://www.nature.com/articles/s41429-023-00653-8.pdf

Reference5 articles.

1. Gaibani P, Giani T, Bovo F, Lonbardo D, Amadesi S, Lazzarotto T, et al. Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in Gram-negative MDR bacilli: molecular mechanisms and susceptibility testing. Antibiotics. 2022;11:628.

2. Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics. 2022;11:723.

3. Gaibani P, Amadesi S, Lazzarotto T, Ambretti S. Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient. J Glob Antimicrob Resist. 2022;30:262-264.

4. Bavaro DF, Belati A, Diella L, Stufano M, Romanelli F. Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives. Antibiotics. 2021;10:652.

5. Gaibani P, Crovara-Pesce C, Lazzarotto T, Pea F, Ambretti S. Evaluation of synergistic activity of fosfomycin in combination with novel ß-lactams/ß-lactamase inhibitor combinations (βL-βLICs) against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Antimicrob Agents. 2022;60:106671.